FDA Approved: Toxic Decayed Meat Being Sold As “Fresh”

Posted on Jan 20, 2016 in News

After reading this you may never trust Congress or the FDA again, let alone corporate chain grocery stores. This toxic practice makes seriously decayed meat look fresh for weeks and is banned in many countries including the European Union and Japan. Many consumers are unaware that over 70% of beef and chicken in the United States and Canada is treated with poisonous carbon monoxide gas and the FDA allows it, despite the known public health risks. A bill was introduced in Congress that would require the labeling of meat that has been treated with carbon monoxide but it was never enacted and...

Read More

FDA: Your Own Cells Are a Drug

Posted on Jan 13, 2016 in News, Political

To protect Big Pharma, the FDA is coming after stem cell therapies. Don’t let the agency classify your body as a pharmaceutical drug. Action Alert! In the next few months, the FDA will hold a public meeting to discuss its recent actions to clamp down on the use of autologous stem cell treatments. This is when a doctor removes adult stem cells from a patient, processes them, and returns the cells to the same patient. The public meeting will discuss four guidance documents the agency has released over the last two years (here, here, here, and here). They are meant to clarify which treatments...

Read More

FDA Prepares to Fast Track New Vaccines Targeting Pregnant Women

Posted on Nov 18, 2015 in News, Vaccines

FDA Prepares to Fast Track New Vaccines Targeting Pregnant Women Vaccine manufacturers and federal health officials want to fast track to licensure new experimental vaccines targeting pregnant women with the goal of preventing certain kinds of infections in newborn infants. On Nov. 13, 2015, the FDA Vaccines & Related Biological Products Advisory Committee (VRBPAC) convened a one day public meeting at the FDA headquarters in Silver Spring, MD to discuss proposed changes to FDA requirements for licensure of vaccines intended for use during pregnancy.   NVIC representatives attending the...

Read More

Dr. Buttar to speak in Fort Wayne, Indiana – Come Join In!!!

Posted on Mar 30, 2015 in News

Advanced Medicine for Optimal Health with Dr. Rashid A. Buttar Saturday, April 25, 2015 9:15 AM to 3:00 PM (EDT) Fort Wayne, Indiana   Come meet Dr. Rashid A. Buttar and learn his advanced protocols which he has found much success with in bringing his patients to Optimal Health. Doors will open at 9:15 am. Light refreshments provided. This will be an all day event with seminar beginning at 10am and finishing at 3pm Lunch will be provided at 12p   Seminar to be held at: The Hyatt 111 W. Washington Center Rd Fort Wayne, IN 46825 Phone: 260-471-8522 .. Hosted by Optimum Health PMMA   To...

Read More

How the Government has Earned $3.5 BILLION from the Claim that Vaccines Don’t Cause Autism

Posted on Feb 3, 2015 in Autism, Heavy Metals, Medical Rewind, News, Political

Few among the American public truly understand just how huge the U.S. vaccine market is. Not only do drug companies reap huge profits from vaccines, so too does the U.S. government. For example, did you know that the U.S. Department of Health and Human Services has accumulated $3.5 BILLION in vaccine tax revenue which is currently “sitting” in the Vaccine Injury Compensation Trust Fund? This trust fund was established in 1988 “to compensate vaccine-related injury or death claims for covered vaccines.” The money in this fund comes from a $0.75 excise tax on vaccines recommended by the CDC. In...

Read More

U.S. FDA approves AbbVie hepatitis C drug, costs $83,319 for 12 weeks

Posted on Feb 3, 2015 in News

U.S. health regulators on Friday approved AbbVie’s all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12-week plan, a bit below its huge selling competitor Sovaldi from Gilead Sciences. Gilead’s Sovaldi treatment stole headlines last year with its $84,000 price tag and set off a national debate about whether drug prices have climbed too high. AbbVie’s newly approved regimen is also less costly than Gilead’s newest one-pill regimen that combines Sovaldi with another drug and costs $94,500 for 12 weeks. With Gilead’s...

Read More